Ropes & Gray advised Acumen Pharmaceuticals on the transaction.Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will explore…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
